Medical science faces great difficulty in treating Benign Paroxysmal Positional Vertigo (BPPV), which is characterised by a high prevalence of misdiagnosis and protracted patient suffering. Given that 1.4% of people visit emergency rooms each year as a result of BPPV incidents and that 4% of the population is impacted by it, it is critical to diagnose and treat BPPV patients effectively. Traditional approaches, however, frequently fall short, resulting in repeated hospital stays and extended periods of agony for patients. SYG MED stands out as an innovative and hopeful light in this world of uncertainty and frustration. 

The ground-breaking robotic treatment technology from SYG MED provides a revolutionary approach to treating the intricacies of BPPV. It is impossible to overestimate SYG MED’s contribution to the revolution of BPPV treatment, given its astounding success rate of 96.7% and its 20-minute average diagnosis and treatment duration. SYG MED gives patients the power to restore their quality of life and end their suffering by arming doctors with the instruments and technology they need to provide accurate and efficient care.  

With its headquarters located in Istanbul, Turkey, SYG MED was founded in 2018 with the goal of transforming the management of benign paroxysmal positional vertigo (BPPV). The company is at the forefront of medical innovation. Under the direction of renowned doctors and engineers, such as Prof. Dr. Tarik Ozkul (CEO), Prof. Dr. M. Haluk Ozkul (CMO-MD), and Mr Burhan Ozmen (COO), SYG MED has developed a novel robotic treatment system that is intended to precisely and efficaciously address the problems associated with BPPV. 

About 4% of the population has BPPV, which makes diagnosis and therapy extremely difficult. Patients frequently experience debilitating vertigo sensation and many hospital visits as a result of misdiagnosis rates that range from 74% to 81%, with established treatment options proving ineffective. With an impressive 96.7% success rate and a 20-minute average diagnosis and treatment duration, SYG MED’s robotic treatment system is a ray of hope. 

The creation of specialised vertigo treatment centres manned by qualified medical personnel and outfitted with cutting-edge equipment forms the foundation of SYG MED’s objective. SYG MED hopes to broaden its influence and reach with this creative business plan, guaranteeing that patients anywhere may receive efficient BPPV therapy. SYG MED offers a wide range of therapy manoeuvres, comprising 22 variant manoeuvres and 11 classical treatment manoeuvres. This makes it a promising choice for patients who have tried every conventional treatment available. 

The many clinical trial success stories attest to the effectiveness of SYG MED’s ground-breaking methodology. SYG MED has been internationally acknowledged for its contributions to humanity, which range from patients regaining their freedom and quality of life after years of suffering to elderly people receiving quick relief. The business received the esteemed Sustainability Award in 2023 in recognition of its dedication to patient care and social impact. 

Serving prestigious clients like Haseki Hospital and the MedicalPark Hospital Chain with pride is a tribute to SYG MED’s dedication to quality and innovation. The organisation has received numerous major accolades in recognition of its commitment to leading the way in medical technology breakthroughs. SYG MED has continuously proven its capacity to push the limits of medical innovation, as evidenced by its receipt of awards such as the ISIF Patent Award in 2019 and the DoctorsClub Award for Most Innovative Product of the Year in 2021. 

SYG MED’s reputation as a leader in the industry is further reinforced by the 2022 TET ARGE Award for Smart Medicine and its participation in the Create The Future Award’s Top 100 innovations. Furthermore, SYG MED’s status as a pioneer in medical technology with a significant worldwide influence was cemented in 2024, when the company’s persistent dedication to social impact was recognised with the BIGG SPORT AWARD.

“Our goal is to make our technology accessible to all people, anywhere in the world. That’s why we have adopted the revenue share model, which costs very little for the hosting institution to start. We hope to be remembered as a group that benefits humanity,” says Prof. Dr Tarik Ozkul, CEO of SYG MED.

SYG MED’s dedication to innovation and accessibility is as strong as it looks to the future. Through promoting the incorporation of their robotic manoeuvring system into emergency room environments and partnering with global medical specialists, SYG MED hopes to transform BPPV treatment globally.